BLA 761240 · Coherus Biosciences INC
Loqtorzi
Toripalimab-Tpzi · Injection · Programmed Death Receptor-1 Blocking Antibody
NovelBreakthrough therapyPriority reviewOrphanCDER novel approval, Oct 27, 2023: To treat recurrent or metastatic nasopharyngeal carcinoma when used together with or following other therapies
Last checked: Nov 20, 2026Latest source record: Aug 31, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
Oct 27, 2023
Approved uses
n/a
Original approval plus efficacy supplements
Registered trials
655
84 Phase 3, 218 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. FDA's summary: To treat recurrent or metastatic nasopharyngeal carcinoma when used together with or following other therapies
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
No approvals could be loaded from Drugs@FDA just now.
Clinical trials
Interventional ClinicalTrials.gov studies with "Toripalimab" as an intervention, any sponsor and status, largest first.
- Surgery vs. Radical Chemoradiotherapy for Esophageal SCC After Neoadjuvant ImmunochemotherapyPivotal-lookingRecruiting
Henan Cancer HospitalGovernment (non-federal)
NCT07629817 · 1,044 participants (planned) · Start Jun 16, 2026 · Primary completion Mar 15, 2032
Drug: Toripalimab + Nab-paclitaxel + Platinum-based Chemotherapy · For: Esophageal Squamous Cell Carcinoma
Sites: Zhengzhou, China
- PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric CancerPivotal-lookingActive, not recruiting
Shanghai Junshi Bioscience Co., Ltd.Academic, hospital or other
NCT05180734 · 878 participants · Start Feb 10, 2022 · Primary completion Mar 31, 2027
Drug: JS001/Placebo; JS001/placebo combine with Postoperative Adjuvant Chemotherapy · For: Gastric or Esophagogastric Junction Adenocarcinoma
Sites: Bengbu, China; Chizhou, China; Beijing, China · 71 sites in all
Shanghai Junshi Bioscience Co., Ltd.Academic, hospital or other
NCT07309276 · 864 participants (planned) · Start Jan 23, 2026 · Primary completion Nov 30, 2027
Drug: JS212 for Injection; JS207 for Injection and 2 more · For: Advanced Lung Cancer
Sites: Shanghai, China
- Adaptive Immunotherapy for Nasopharyngeal CarcinomaPivotal-lookingRecruiting
Sun Yat-sen UniversityAcademic, hospital or other
NCT07154069 · 802 participants (planned) · Start Nov 13, 2025 · Primary completion Sep 2031
Drug: Capecitabine; Concurrent chemoradiotherapy (cCRT) and 1 more · For: Nasopharyngeal Cancinoma (NPC)
Sites: Guangzhou, China
- Comparison of Perioperative Immunotherapy, Adjuvant Immunotherapy or Neoadjuvant Immunotherapy for Resectable Stage II-IIIA NSCLCPivotal-lookingRecruiting
Fudan UniversityAcademic, hospital or other
NCT07554846 · 759 participants (planned) · Start May 1, 2026 · Primary completion May 1, 2030
Drug: Peroperative immunotherapy; Neoadjuvant immunotherapy and 1 more · For: Resectable Stage II-IIIa NSCLC
Sites: Shanghai, China
- Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)Pivotal-lookingRecruiting
Shanghai Junshi Bioscience Co., Ltd.Academic, hospital or other
NCT06095583 · 756 participants (planned) · Start Nov 15, 2023 · Primary completion Jul 31, 2027
Drug: Tifcemalimab injection; toripalimab injection and 2 more · For: Limited-stage Small Cell Lung Cancer (LS-SCLC)
Sites: Harbin, China; Changsha, China; Nanchang, China · 76 sites in all
LaNova Medicines Zhejiang Co., Ltd.Industry
NCT05934331 · 632 participants (planned) · Start Jul 27, 2023 · Primary completion Aug 6, 2031
Drug: LM-302; Toripalimab and 9 more · For: Malignant Neoplasms of Digestive Organs
Sites: Shanghai, China
- JS107 in Combination With Toripalimab and Chemotherapy for the Treatment of CLDN18.2-positive Gastric or Gastroesophageal Junction AdenocarcinomaPivotal-lookingRecruiting
NingBo Junyan Hongshi Biosciences Co., LtdIndustry
NCT07584135 · 600 participants (planned) · Start May 28, 2026 · Primary completion Jan 31, 2029
Drug: Injection JS107&Toripalimab& Oxaliplatin Injection& Capecitabine; Sintilimab& Oxaliplatin Injection& Capecitabine · For: Gastric Adenocarcinoma
Sites: Guangzhou, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part B: Loqtorzi (Toripalimab-Tpzi) · HCPCS J3263
2024 spending
$2.0M
Beneficiaries
56
222 claims
Per beneficiary
$36,269
2024 ASP limit $39.07 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $2,031,091 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: The JUPITER-02 Randomized Clinical Trial.
Mai HQ, Chen QY, Chen D, et al. · JAMA 2023 · Clinical Trial, Phase III, Comparative Study
- Neoadjuvant GOLP in Resectable High-Risk Intrahepatic Cholangiocarcinoma.
Shi GM, Huang XY, Liang F, et al. · N Engl J Med 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
- Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non-Small Cell Lung Cancer: The Neotorch Randomized Clinical Trial.
Lu S, Zhang W, Wu L, et al. · JAMA 2024 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer.
Sheng X, Zeng G, Zhang C, et al. · N Engl J Med 2025 · Randomized Controlled Trial, Multicenter Study
- Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial.
Wang ZX, Cui C, Yao J, et al. · Cancer Cell 2022 · Clinical Trial, Phase III, Multicenter Study
- Toripalimab Combination Therapy Without Concurrent Cisplatin for Nasopharyngeal Carcinoma: The DIAMOND Randomized Clinical Trial.
Xu C, Liang XY, Huang XQ, et al. · JAMA 2025 · Clinical Trial, Phase III, Equivalence Trial
Sponsor: Coherus Biosciences INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.